Drug Profile
Eculizumab biosimilar - Polpharma Biologics
Alternative Names: BOW 080Latest Information Update: 26 Oct 2021
Price :
$50
*
At a glance
- Originator Bioceros
- Developer EPIRUS Biopharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antihypertensives; Antipsoriatics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies; Urologics
- Mechanism of Action Complement C5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 13 Jul 2020 Polpharma Biologics acquired Bioceros and changed name to Polpharma Biologics
- 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
- 16 Nov 2015 Early research in Haemolytic uraemic syndrome in USA (unspecified route)